Cytos secures eleventh-hour reprieve with €37m from venBio-led syndicate
This article was originally published in Scrip
Executive Summary
The Swiss immunotherapy firm Cytos Biotechnology has secured a financial lifeline from a syndicate of investors led by venBio and including Amgen, Abingworth and Aisling Capital. A €37 million debt and equity financing will recapitalise the company and provide funds to progress its lead programme, a vaccine for allergic asthma.